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ABSTRACT
We demonstrate here that the G protein-coupled receptor (GPCR), sphingosine 
1-phosphate receptor 2 (S1P2, Mr = 40 kDa) is shed in hsp70+ and CD63+ containing 
exosomes from MDA-MB-231 breast cancer cells. The receptor is taken up by 
fibroblasts, where it is N-terminally processed to a shorter form (Mr = 36 kDa) that 
appears to be constitutively active and able to stimulate the extracellular signal 
regulated kinase-1/2 (ERK-1/2) pathway and DNA synthesis. An N-terminally 
truncated construct of S1P2, which may correspond to the processed form of the 
receptor generated in fibroblasts, was found to be constitutively active when over-
expressed in HEK293 cells. Analysis based on the available crystal structure of the 
homologous S1P1 receptor suggests that, in the inactive-state, the N-terminus of 
S1P2 may tension TM1 so as to maintain a compressive action on TM7. This in turn 
may stabilise a closed basal state interface between the intracellular ends of TM7 and 
TM6. Cleavage and removal of the S1P2 N-terminal peptide is postulated to facilitate 
relaxation of TM1 and accompanying separation of TM6 and TM7. The latter transition 
is one of the key elements of G protein engagement and is required to open the 
intracellular coupling interface beneath the GPCR helix bundle. Therefore, removal at 
the N-terminus of S1P2 is likely to enhance G protein coupling. These findings provide 
the first evidence that S1P2 is released from breast cancer cells in exosomes and is 
processed by fibroblasts to promote ERK signaling and proliferation of these cells.
INTRODUCTION
The bioactive lipid, sphingosine 1-phosphate 
(S1P) is formed by the sphingosine kinase-catalysed 
phosphorylation of sphingosine. There are two isoforms 
of sphingosine kinase, termed SK1 and SK2, which are 
encoded by different genes and exhibit distinct sub-
cellular localisation and biochemical properties and can 
regulate overlapping and non-overlapping signaling 
pathways in cancer cells [1]. In addition to its biosynthesis, 
the level of S1P is controlled by degradation reactions 
catalysed by S1P lyase, to produce (E)-2-hexadecenal and 
phosphoethanolamine, and by S1P phosphatase, which 
dephosphorylates S1P to regenerate sphingosine [1]. 
S1P can be released from cells via specific transporters 
in the plasma membrane and then bind to and stimulate 
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a family of G protein-coupled receptors (GPCRs), the 
S1P receptors (S1P1-S1P5) on cells to induce biological 
responses [1].
S1P2 is coupled to Gi, Gq and G12/13 and can regulate 
phospholipase C, Rho, Rho-dependent kinase and 
extracellular signal regulated kinase (ERK-1/2) pathways 
[2–4]. The receptor is localised to the plasma-membrane 
and is internalised in response to ligand stimulation [5, 6]. 
This involves β-arrestin-2 and G protein-coupled receptor 
kinase 2 (GRK-2)-dependent mechanisms. S1P binding to 
S1P2 also inhibits the phosphatidylinositol 3-kinase/Akt 
pathway via a Rho-dependent activation of phosphatase 
and tensin homolog (PTEN) to inhibit cell migration [7, 
8]. S1P2 is also involved in regulating the hippo pathway 
[10] and activation of the transcription factors, YAP and 
TAZ [9, 10].
There is substantial evidence demonstrating that 
S1P plays a significant role in cancer, including regulating 
transformation, epithelial-mesenchymal transition, 
invasiveness, cancer cell survival, replicative immortality, 
tumour neovascularisation and metabolism [11]. 
Nevertheless, the role of S1P2 in cancer is controversial 
with evidence demonstrating that this receptor can 
both promote and inhibit tumorigenesis. For example, 
S1P2 inhibits the motility of cancer cells [12, 13], and 
high expression of S1P2 in the nucleus of tumours from 
ER+ breast cancer patients is associated with improved 
prognosis [14]. However, recent studies have shown that 
S1P formed by host SK1 and acting via S1P2 prevents 
induction of the metastasis suppressor, Brms1 (breast 
carcinoma metastasis suppressor 1), thereby promoting 
metastatic spread [15]. SK1 activation and localization 
to the plasma membrane, with subsequent activation 
of S1P2 by released S1P (‘inside-out’ signaling) also 
upregulates transferrin receptor 1 (TFR1) expression, 
which contributes to SK1-mediated oncogenesis [16]. 
Furthermore, SK1-derived S1P, acting on S1P2, inactivates 
PP2A and prevents dephosphorylation of the oncogenic 
fusion protein, Bcr-Abl, thereby increasing its stability in 
CML [17]. We have also demonstrated that the function of 
S1P2 can change dependent on its subcellular localisation 
[18]. We reported that the SK2 inhibitor, (R)-FTY720 
methyl ether (ROMe) or siRNA knockdown of SK2 
promoted the accumulation of S1P2 in the nucleus of 
MDA-MB-231 breast cancer cells and this was associated 
with growth arrest [18]. Additionally, the S1P4 antagonist, 
CYM50367 or siRNA knockdown of S1P4 promoted 
nuclear localisation of S1P2, indicating that S1P2 and S1P4 
are closely linked functionally to prevent accumulation of 
S1P2 in the nucleus, and to thereby promote breast cancer 
cell growth [18]. Whether the effect of nuclear localised 
S1P2 on growth is a cancer-specific phenomenon requires 
further investigation.
Recently, SK1 was demonstrated to be released as 
a catalytically active enzyme in vesicles shed by human 
breast carcinoma 8701-BC cells [19]. We therefore 
considered the possibility that S1P receptors might also 
be shed from cancer cells in exosomes to enable cancer 
cell/fibroblast communication, critical for metastasis. 
Exosomes are cell-derived vesicles of ~ 100 nm diameter 
which are released from cells by fusion of multi-vesicular 
bodies (MVB) with the plasma membrane [20–22]. They 
are formed from intraluminal endosomal vesicles and 
contain proteins, miRNA, lipids and other constituents 
that can enable cellular communication once released. 
This indicates that endosomal recycling is a critical 
step in exosome formation. Exosomes are taken up by 
recipient cells by membrane fusion and/or utilization of 
the transferrin endocytic machinery.
We demonstrate herein, for the first time, that S1P2 
is shed from breast cancer cells in exosomes and, when 
exposed to fibroblasts, is processed to a shorter form and 
taken up by these cells, whereupon it promotes activation 
of the ERK-1/2 pathway and stimulates proliferation of 
these cells. These findings suggest a novel functional 
signaling role for the processed short form of S1P2. Future 
studies are required to evaluate the role of this processed 
short form in regulating inter-cellular communication 
between cancer cells and fibroblasts and whether it can 
promote fibroblast transformation and enhance metastatic 
spread.
RESULTS
S1P2 is shed from MDA-MB-231 breast 
cancer cells
Using proteomic analysis, Amorim et al. [23] 
found that extracellular vesicles [EVs, sedimentation 
at 100,000 g (100K) and 20,000 g (20K)] derived from 
HER2-expressing immortalized human mammary luminal 
epithelial HB4a and C5.2 cells contain S1P3 (exclusively 
in 20K EVs) and S1P4 (exclusively in 100K EVs) 
[23]. This was of interest because we have previously 
demonstrated that HER2 cooperates with S1P4 to regulate 
the ERK-1/2 pathway in MDA-MB-453 cells [24]. Indeed, 
we show here that S1P4 is released from MDA-MB-453 
cells into conditioned medium (CM) (Figure 1A). S1P4 
is expressed as 2 immunoreactive proteins with a Mr of 
38-40 kDa in lysates of MDA-MB-453 cells and only 
one of these is released from these cells into CM (Figure 
1A). Since, we have also demonstrated that S1P2 and S1P4 
are functionally linked in MDA-MB-231 cells [18], we 
assessed whether these receptors are also released into CM 
from these cells. In this regard, S1P2 (Mr = 40 kDa) is 
released into CM from MDA-MB-231 cells (Figure 1B), 
while S1P4 is not released (Figure 1C). S1P4 is expressed 
as 2 immunoreactive proteins with a Mr of 38-40 kDa in 
lysates of MDA-MB-231 cells (Figure 1C). In addition, 
we found that S1P2 is not released into CM from MDA-
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MB-453 cells (Figure 1D). Therefore, these findings 
indicate that there is specificity in terms of the receptor 
sub-type released from these two breast cancer cell lines.
We next investigated the effect of CM isolated 
from MDA-MB-231 or MDA-MB-453 cells on mouse 
embryonic fibroblasts (MEFs) to establish whether S1P2 
or S1P4 in CM might promote signaling in fibroblasts. 
In this regard, treatment of MEFs with CM from MDA-
MB-231 cells induced a strong activation of ERK-1/2 
(Figure 2A, Supplementary Figure 1) and promoted DNA 
synthesis (Figure 2B). Interestingly, the endogenous S1P2 
receptor that is expressed in MEFs does not promote DNA 
synthesis in response to CYM5520 (Figure 2B), which is 
a potent and highly selective S1P2 allosteric agonist [25]. 
These findings suggest that the exosomal S1P2 receptor 
derived from breast cancer cells behaves differently from 
the endogenous S1P2 receptor that is expressed in MEFs.
We next assessed whether the S1P2 receptor 
released into CM from breast cancer cells requires S1P 
in order to activate ERK-1/2 signaling in MEFs. This was 
achieved using JTE-013, which is a competitive S1P2/4 
antagonist [24]. The idea here is that if S1P is required, 
then activation of ERK-1/2 in MEFs in response to CM 
should be blocked by JTE-013. Basal ERK-1/2 signaling 
in MEFs was partially reduced by JTE-013 (Figure 2A, 
Supplementary Figure 1). However, JTE-013 had no effect 
on the ERK-1/2 activation induced by CM (Figure 2A, 
Supplementary Figure 1). These findings suggested either 
that stimulation of the ERK-1/2 pathway in fibroblasts was 
not mediated by the S1P2 shed from MDA-MB-231 cells 
into CM or that the released S1P2 might be processed to a 
form that does not require S1P and is therefore insensitive 
to inhibition by JTE-013. Confirmation that the S1P2 
shed from MDA-MB-231 cells does in fact mediate the 
stimulatory effect of CM on ERK-1/2 activation in MEFs 
was obtained using siRNA to knockdown expression of 
S1P2 in MDA-MB-231 cells (Figure 2C, Supplementary 
Figure 2). Thus, CM isolated from siRNA S1P2 treated 
MDA-MB-231 cells failed to activate ERK-1/2 in MEFs 
(Figure 2C).
The increase in ERK-1/2 activation in MEFs 
in response to CM was not due to the uptake of 
phosphorylated ERK-1/2 as the kinase was not released 
from MDA-MB-231 cells into the CM, but was detected 
with either anti-ERK-2 or anti-phospho ERK-1/2 
antibodies in lysates of MDA-MB-231 cells (Figure 2D). 
Specificity for S1P2 was confirmed by the demonstration 
that CM containing S1P4 from MDA-MB-453 cells failed 
to stimulate the ERK-1/2 pathway in MEFs (Figure 2E, 
Supplementary Figure 3). We therefore focussed our 
investigation on S1P2.
To establish whether exosomes are released from 
MDA-MB-231 cells, we transiently over-expressed 
the exosomal markers, GFP-hsp70 or mCherry-tsg101 
(Figure 3A). These proteins were subsequently found in 
CM isolated from these cells (Figure 3B), suggesting that 
export of S1P2 might indeed be via exosomes. Indeed, 
CM from MDA-MB-231 cells over-ovexpressing HA-
tagged S1P2 also contained the receptor (Figure 3B). We 
next purified exosomes from the CM of MDA-MB-231 
cells by ultracentrifugation. The exosome preparation 
contained S1P2 (Mr = 40 kDa) and the exosomal markers, 
Figure 1: Identification of S1P4 and S1P2 shed from breast cancer cells. (A) Western blot with anti-S1P4 antibody showing 
the presence of S1P4 in MDA-MB-453 cell lysate (453CL) and acid precipitates (PPT) of conditioned medium (CM) isolated after 48 h 
incubation with opti-MEM. (B) Western blot with anti-S1P2 antibody showing the presence of S1P2 in MDA-MB-231 cell lysate (231CL) 
and acid precipitates (PPT) of conditioned medium (CM) isolated after 48 h incubation with opti-MEM. (C) Western blot with anti-S1P4 
antibody showing the absence of S1P4 in acid precipitates (PPT) of conditioned medium (CM) isolated from MDA-MB-231 cells after 48 
h incubation with opti-MEM. The presence of S1P4 in cell lysates (231CL) of MDA-MB-231 cells is also shown. (D) Western blot with 
anti-S1P2 antibody showing the absence of S1P2 in acid precipitates (PPT) of conditioned medium (CM) isolated from MDA-MB-453 
cells after 48 h incubation with opti-MEM. The presence of S1P2 in cell lysates (453CL) of MDA-MB-453 cells is also shown. Results are 
representative of 3 independent experiments.
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Figure 2: Effect of CM from MDA-MB-231 cells on ERK-1/2 activation and DNA synthesis in MEFs. MEFs quiescent for 
24 hr were treated with non-conditioned medium (NCM) or conditioned medium (CM) from MDA-MB-231 cells for 10 min. MEFs were 
pre-treated with and without JTE-013 (10 μM) for 15 min prior to addition of NCM or CM. MEFs were also treated with CYM5520 (10 
μM) in the DNA synthesis experiments. CM was also isolated from MDA-MB-231 cells treated with scrambled or S1P2 siRNA for 24 h. 
(A) Western blot showing the effect of CM from MDA-MB-231 cells and JTE-013 on ERK-1/2 activation in MEFs. (B) Bar graph showing 
the effect of NCM, CM from MDA-MB-231 cells or CYM5520 on [3H]-thymidine incorporation into DNA synthesis in MEFs. Results 
are expressed as means +/- SEM for n=3. (C) Western blot showing the effect of CM on ERK-1/2 activation in MEFs. CM was isolated 
from MDA-MB-231 cells that had been treated with either scrambled siRNA (200 nM) or S1P2 siRNA (100 or 200 nM). Also shown is the 
effect of S1P2 siRNA on S1P2 expression levels in MDA-MB-231 cells. (D) Western blot showing that neither P-ERK-1/2 nor ERK-2 is 
released from MDA-MB-231 cells into CM as evidenced by their absence in the PPT. (E) Western blot showing the lack of effect of CM 
from MDA-MB-453 cells on ERK-1/2 activation in MEFs. Blots were probed with anti-phospho ERK-1/2 and anti-S1P2 antibodies. (A, C, 
D, E). Blots were re-probed with anti-actin antibody to ensure equal protein loading (A, C, E). Results (A, C, D, E) are representative of 3 
independent experiments.
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Figure 3: Identification of S1P2 in exosomes shed from MDA-MB-231 breast cancer cells. (A) Western blot with anti-GFP 
or anti-mCherry antibodies showing the over-expression of GFP-hsp70 and mCherry-tgs101 in vector (V) or plasmid transfected MDA-
MB-231 cells for 24 or 48 h. (B) Western blot with anti-GFP or anti-mCherry or anti-HA antibodies showing the presence of GFP-hsp70, 
mCherry-tsg101 or HA tagged S1P2 (Mr = 40 kDa) in transfected MDA-MB-231 cell lysate (CL) and acid precipitates (PPT) of CM. (C) 
Western blot with anti-hsp70, anti-CD63 and anti-S1P2 antibodies showing the presence of GFP-hsp70, CD63 or S1P2 in MDA-MB-231 
cell lysates (CL) and isolated exosomes (EXO) from CM. (D) Immunofluorescence image of MDA-MB-231 cells stained with anti-CD63/
TRITC (red) secondary and anti-S1P2/FITC (green) secondary antibodies showing co-localisation (yellow) of CD63 and S1P2 in large 
vesicles typical of MVBs. (E) Electron micrograph of immunogold staining with anti-CD63 [attached to secondary goat anti-mouse IgG-
immune-gold particles (15 nm)] and anti-S1P2 antibodies [attached to secondary goat anti-rabbit IgG-immune-gold particles (10 nm)] in 
exosomes isolated from CM of MDA-MB-231 cells. Control represents exosomes that have not been incubated with primary antibody. 
Results are representative of 3 independent experiments.
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CD63 and GFP-hsp70, which were detected by Western 
blot analysis (Figure 3C). MDA-MB-231 cells were also 
immunostained with anti-S1P2 antibody and anti-CD63 
antibody (marker of MVB and exosomes) in order to 
track these proteins inside MDA-MB-231 cells. CD63 was 
present in large intracellular vesicles typical of MVBs that 
co-localised with S1P2 (Figure 3D). Finally, the exosome 
preparation was immunostained with anti-CD63 and anti-
S1P2 antibodies using secondary gold linked antibodies 
and subjected to electron microscopy. Using this approach, 
purified exosomes were shown to contain CD63 and S1P2 
(Figure 3E).
Processing of exosomal S1P2 by fibroblasts
MEFs express endogenous S1P2 (Mr = 40 kDa). 
However, the endogenous S1P2 receptor does not promote 
activation of the ERK-1/2 pathway in response to 
CYM5520 (Figure 4A). Therefore, the endogenous S1P2 
receptor and exosomal S1P2 receptor released from MDA-
MB-231 cells can be distinguished from one another by 
their different abilities to stimulate the ERK-1/2 pathway 
(Figure 2A) and DNA synthesis (Figure 2B) in MEFs.
We also treated MEFs with CM from MDA-
MB-231 cells and performed western blot analysis with 
anti-S1P2 antibody in order to establish whether the breast 
cancer S1P2 receptor is taken up by fibroblasts from 
CM or exosomes. Indeed, S1P2 (Mr = 40 kDa) released 
from breast cancer cells was found to be taken up by 
MEFs, but appeared to be processed to a shorter form 
(Mr =36 kDa) (Figure 4B). The shorter form of S1P2 is 
likely to be proteolysed at the N-terminus of the receptor 
by proteinases expressed in MEFs, since the anti-S1P2 
antibody is raised to the C-terminal region of S1P2.
Based on these findings, we propose that the short 
form of S1P2 is able to adopt a conformation that enables 
it to stimulate the ERK-1/2 pathway in MEFs. JTE-
013 had no effect on the amount of the short S1P2 form 
taken up by the fibroblasts (Figure 4B). There is a low-
level expression of the short form of endogenous S1P2 
in MEFs and which is evident in cells treated with NCM 
(Figure 4B). Interestingly, the appearance of this shorter 
form is abolished when MEFs are treated with JTE-013 
(Figure 4B). This is important for two reasons. First, the 
processing of endogenous S1P2 is distinguishable from 
the formation of the short form derived from breast cancer 
cells, which is insensitive to JTE-013. Second, the findings 
might suggest MEFs release S1P and that this stimulates 
a small fraction of S1P2, perhaps inducing a conformation 
and/or localisation that renders it susceptible to processing. 
In addition, JTE-013 reduces the basal activation state of 
ERK-1/2 in MEFs (Figure 2A, Figure 4B), suggesting that 
processing of the endogenous receptor renders it capable of 
stimulating the ERK-1/2 pathway. The allosteric agonist, 
CYM5520 (which is not a sphingophospholipid-mimetic 
ligand) did not activate the ERK-1/2 pathway (Figure 4A) 
and failed to increase formation of the endogenous short 
form of S1P2 (Figure 4B) suggesting that it does not induce 
a conformation of S1P2 that enables its processing. In 
contrast, the exosomal S1P2 receptor released from MDA-
MB-231 cells is processed to the short form, presumably 
because it is immediately accessible to a putative protease 
expressed in MEFs and this is independent of S1P and 
therefore insensitive to JTE-013.
The endogenous S1P2 receptor in MEFs is 
functional, as CYM5520 induced rounding of MEFs and 
prevented actin localisation in lamellipodia, consistent 
with an inhibitory role of S1P2 in regulating a migratory 
phenotype in MEFs (Figure 4C). This might be mediated 
through G12/13 coupling and RhoA activation. CM from 
MDA-MB-231 cells also caused rounding of MEFs 
and prevented actin localisation in lamellipodia (Figure 
4C), suggesting that the processed short S1P2 receptor 
form might exist in a conformation that is capable of 
concomitantly inducing both cell rounding and activation 
of the ERK-1/2 pathway. We also co-stained the fibroblasts 
with anti-S1P2 antibody and demonstrated that CM and 
CYM5520 promoted the redistribution of S1P2 into the 
nucleus of these cells (Figure 4C), although this is not 
linked with either ERK-1/2 signaling or DNA synthesis as 
CYM5520 does not stimulate these processes. The S1P2 
receptor was detected in vesicle like structures, perhaps 
indicative of ‘on-going’ endocytosis. The significance of 
the re-localisation of S1P2 to the nucleus in response to 
CM in terms of promoting MEF proliferation requires 
further investigation.
To provide additional evidence that exosome cargo 
can be transferred from MDA-MB-231 cells to MEFs, we 
showed that exosomal GFP-hsp70 was also taken up by 
MEFs, detected using fluorescence microscopy (Figure 
4D).
Exosomal S1P2 from MDA-MB-231 cells 
activates fibroblasts
We next tested the effect of purified exosomes on 
MEFs. In this regard, addition of purified exosomes from 
scrambled but not S1P2 siRNA-treated MDA-MB-231 
cells promoted activation of ERK-1/2 in MEFs (Figure 
5A, Supplementary Figure 4). We also subjected MEFs 
to western blot analysis after incubation with the purified 
exosomes. These experiments demonstrated that S1P2 was 
taken up by MEFs and processed to a short form, detected 
at Mr = 36 kDa, after incubation with exosomes (Figure 
5B).
Effect of truncated S1P2 on ERK-1/2 signaling in 
HEK293 cells
Inspection of the S1P2 receptor amino acid sequence 
reveals a potential intramembrane metalloprotease cleavage 
site corresponding to Ala-Ser-Ala-Phe-Iso-Val near the 
Oncotarget29459www.oncotarget.com
Figure 4: Uptake of exosomal S1P2 from breast cancer cells and processing by MEFs. MEFs quiescent for 24 hr were treated 
with NCM or CM from MDA-MB-231 cells for 10 min. MEFs were pre-treated with and without JTE-013 (10 μM) or CYM5520 (10, 25 
μM) for 15 min prior to addition of NCM or CM. (A) Western blot showing the lack of effect of CYM5520 alone on ERK-1/2 activation 
in MEFs. (B) Western blot showing the uptake into MEFs of the short S1P2 (Mr = 36 kDa) form and the activation of ERK-1/2 in response 
to CM isolated from MDA-MB-231 cells. (A) and (B) Blots were re-probed with anti-actin antibody to ensure equal protein loading. 
(C) Immunofluorescence images of control, CM-stimulated and CYM5520 (10 μM)-stimulated MEFs co-stained with anti-actin (TRITC 
secondary antibody, red) and anti-S1P2 (FITC secondary antibody, green) antibodies. (D) Fluorescence image of MEFs showing uptake of 
GFP-hsp70 by detection of GFP and co-stained with anti-actin antibody using a Texas Red conjugated secondary antibody or DAPI. Results 
are representative of 3 independent experiments.
Oncotarget29460www.oncotarget.com
N-terminus (Figure 6A). We therefore sub-cloned a 
truncated S1P2 mutant corresponding to a processed form of 
the receptor at this site. Two truncated S1P2 forms, lacking 
the first 37 amino acids, were created with either one or 
with two N-terminal HA tags whereas the WT S1P2 has 3 
N-terminal HA tags. Over-expression of the truncated 1x 
and 2x tagged HA-S1P2 receptor in HEK293 cells resulted 
in constitutive activation of ERK-1/2, while the WT S1P2 
receptor failed to activate ERK-1/2 (Figure 6B).
S1P receptor structure-function analysis
The S1P2 receptor exhibits strong sequence 
homology to S1P1, which has recently been characterised 
by co-crystal structures (PDB: 3V2W, 3V2Y) obtained 
with the bound sphingophospholipid-mimetic antagonist, 
ML056 [26]. The typical 7TM GPCR architecture is 
conserved in the S1P1 crystal structure, but a distinctive 
feature is the presence of an N-terminal capping 
helix (S1P1 22-YDIIVRHYNYT-32) that engages the 
phosph(on)ate head group of substrate and substrate-
mimetic ligands with a hydrogen bond from Tyr29 (Figure 
7A). A short 9-residue linker connects the N-terminal 
capping helix to the top of the TM1 helix. A closely related 
helix-capped extracellular organisation is seen in the 
lysophosphatidic acid receptor 1 structure [27]. Sequence 
alignment between S1P2 and S1P1 reveals that the core 
28-HYNYT-32 residues of the N-terminal capping helix 
are fully conserved in S1P2 and that the structure of the 
interfacial extracellular loops (ECLs) that pack against 
this helix is also likely to be preserved, including two 
disulfide bridges that contribute to the fold of ECL2 and 
ECL3. Inspection of the S1P1 structure suggests that the 
N-terminal capping helix may tension TM1 and thence 
generate a compressive interface between the intracellular 
end of this helix and TM7 together with the angled 
intracellular helix-8. This may in turn stabilise an inactive 
basal-state packing of TM7 against TM6.
G protein engagement by GPCRs is known to 
involve docking to a cavity generated by movement in 
Figure 5: The effect of exosomal S1P2 on ERK-1/2 signaling and S1P2 processing in MEFs. MEFs quiescent for 24 hr were 
treated for 15 min with exosomes isolated from CM of MDA-MB-231 cells that had been treated with either scrambled siRNA or S1P2 
siRNA for 24 h. (A) Western blot showing the effect of exosomes (EXO, μl) from scrambled siRNA (100 nM) and S1P2 siRNA (200 nM)-
treated MDA-MB-231 cells on ERK-1/2 activation in MEFs. Blots were probed with anti-phospho ERK-1/2 antibody. (B) Western blot 
showing the uptake into MEFs of the short S1P2 (Mr = 36 kDa) form from exosomes (EXO, 50 or 100 μl) isolated from MDA-MB-231 
cells. Blots were probed with anti-S1P2 antibody. (A, B) Blots were re-probed with anti-actin antibody to ensure equal protein loading. 
Results are representative of 2-3 independent experiments.
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the TM helices, notably with an outward movement at 
the cytoplasmic end of TM5 and TM6 accompanied by 
movement of TM7 and the elbow with helix-8 in the 
opposite direction (towards TM1/TM2). Thus, comparison 
of inactive-state crystal structures for the β2 adrenoceptor 
with the receptor’s structure when complexed to G protein 
(PDB: 3SN6) reveals a pronounced outward bend in TM6 
away from TM7 [28]. The structure also suggests that the 
separation between TM6 and TM7 involves a concomitant 
displacement in TM7/helix-8 that is accommodated, in 
part, by tilting in TM1 together with outward bend at 
the cytoplasmic end of this helix (Figure 7B). In some 
GPCRs, an inactive basal-state is stabilised by inter-TM 
polar interactions (e.g. rhodopsin R3.50–E6.30); loosening 
of such ‘latches’ has been proposed to account for basal-
state activity in the case of the β1 adrenoceptor [29]. For 
the S1P receptors, which lack inter-TM ionic latches, the 
N-terminal cap may conceivably serve as a ‘spring clip’ 
to tension TM1 and intracellular loop 1 against TM7/
helix-8, thereby stabilising the closed TM7/TM6 interface. 
Proteolytic cleavage of the S1P2 N-terminal segment 
may allow relaxation in the position of TM1, with the 
resulting movement facilitating TM6/TM7 separation 
and thence opening of the intracellular coupling interface 
to confer constitutive activity (Figure 7B). In contrast, 
agonist-mediated S1P receptor activation is postulated 
to involve placement of hydrophobic ligand subunits 
into a cluster of hydrophobic and aromatic residues in 
the core of the helix bundle, including the TM6 residues, 
Trp2696.48 and Phe2656.44 (S1P1 numbering) [26]. These, 
residues are conserved in other class A GPCRs such as 
rhodopsin and the β2 adrenoceptor. In the case of the 
latter receptor, the crystal structure with bound G protein 
[28] reveals a significant displacement in the cognate 
Phe6.44 residue associated with the outward movement 
of TM6 and separation from TM7. Mutation of these 
residues in S1P1 decreases or abolishes ligand-induced 
ERK phosphorylation by the S1P1 receptor agonist, 
CYM5442, thereby highlighting the likely importance of 
TM6 movement to signaling. We therefore propose that 
whereas agonist binding may actively stabilise receptor 
conformational state(s) that engage partner signaling 
proteins, truncation of the S1P2 N-terminal sequence 
may perturb conformational equilibria by destabilising 
interfaces in receptor states(s) that preclude partner protein 
engagement.
The identity of the protease and precise site for 
proteolytic activation of S1P2 in fibroblasts have yet to be 
defined. We pre-treated cells with the ADAM inhibitor, 
GM6001 and phenoanthrolene which were ineffective 
in inhibiting CM-stimulated ERK-1/2 activation (data 
not shown). Nevertheless, the exploratory HA-tagged 
N-terminal S1P2 receptor, truncated at the site of a 
candidate metalloprotease consensus, was found to 
Figure 6: Overexpression of truncated S1P2 in HEK293 cells. (A) Sequence alignment of the N-terminal region of WT and 
N-terminal HA-tagged full length and truncated S1P2 receptor constructs. (B) Effect of full length and truncated HA-tagged S1P2 on the 
activation of ERK-1/2 in HEK293 cells. Blots were probed with anti-HA-tag antibody, anti-phospho-ERK1/2 antibody and with anti-
ERK-1/2 antibody to ensure equal protein loading. Results are representative of 3 independent experiments.
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constitutively activate ERK-1/2. As shown in Figure 7B, 
however, the truncation site that we explored is actually 
predicted to lie within the membrane embedded region of 
TM1, so that cleavage at this specific site would likely 
require an intramembrane protease. Helix-destabilising 
features that might render the site more accessible to 
protease action appear to be lacking in the S1P2 TM1 
sequence. It is possible, therefore, that the actual site 
of proteolysis may lie somewhat N-terminal to our 
exploratory site, potentially within the extracellular 
linking sequence that connects the N-terminal capping 
helix to the top of TM1.
DISCUSSION
The major finding of this study is that S1P2 (Mr 
= 40 kDa) is shed from MDA-MB-231 cells and taken 
up by fibroblasts, where it appears to be processed at the 
N-terminus to a smaller constitutively active form (Mr 
=36 kDa). S1P2 is present in exosomes derived from 
MDA-MB-231 cells based on several lines of evidence. 
First, S1P2 and CD63 (a marker for exosomes) were co-
localised in large vesicles in MDA-MB-231 cells that 
are typical of MVBs. Second, EM analysis of exosome 
preparations demonstrate vesicle-like structures that 
Figure 7: S1P2 structure-function analysis and constitutive activation hypothesis. (A) The overall structural organisation 
for S1P2 is illustrated with respect to the co-crystal structure (PDB: 3V2Y) of the homologous S1P1 receptor with bound antagonist 
ML056 (green stick). Predicted membrane-spanning regions of the receptor are coloured orange. An N-terminal capping helix (S1P1 
22-YDIIVRHYNYT-32; dark blue ribbon) contributes key engagement residues for ligand phosph(on)ate head groups; residues involved 
in ligand head group binding from the core of the helix (S1P1 28-HYNYT-32) are fully conserved in S1P2. The N-terminal capping helix 
is connected to TM1 by a short linker sequence (8 residues in S1P1, 9 residues in S1P2; light blue ribbon). Extracellular loops are coloured 
grey (ECL1), yellow (ECL2) and cyan (ECL3); ligand engagement features in these are strongly conserved between S1P1 and S1P2 and 
the overall fold, including two disulfide bridges in ECL2/3 (not shown), is also expected to be very similar in S1P2. We postulate that the 
N-terminal cap imposes a ‘spring clip’ positional constraint on TM1 that restrains movement in TM7 and helix-α8 (magenta ribbon) so 
as to stabilise a closed intracellular coupling interface and thus an inactive basal-state conformation; this involves close packing of TM7 
against TM6 at the intracellular junction. (B) Rotated view of the S1P1 receptor illustrating the region (black ribbon) corresponding to 
the cleaved N-terminal segment in our constitutively active S1P2 receptor construct. ECL1-ECL3 are coloured light green in this panel; 
TM1 is highlighted (solid cylinder), with the N-terminal truncation site lying at the black/orange interface. Shown superimposed is the 
cognate TM1 (solid yellow cylinder) from the crystal structure (PDB: 3SN6) of the active-state β2 adrenoceptor bound to G protein. We 
postulate that N-terminal truncation permits relaxation of TM1 in S1P2 (red arrows), allowing adoption of an orientation akin to that for the 
active-state β2 adrenoceptor TM1. This in turn may allow relaxation of TM7 and separation of TM6 (blue arrows) to open the receptor’s 
intracellular coupling interface.
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contain S1P2 and CD63, and this is supported by evidence 
showing S1P2, Hsp70 and CD63 are detected in CM 
and the exosome preparation by Western blot analysis 
with specific antibodies. Topographical arrangement of 
S1P2 in exosomes and uptake into the plasma-membrane 
of recipient cells would place its C-terminal tail on the 
cytoplasmic side of the recipient cell, thereby enabling 
the short form of S1P2 to initiate signaling into the 
intracellular compartment of MEFs.
The finding that S1P2 can be released from breast 
cancer cells in exosomes raises questions as to what 
factors determine this release. In this regard, Kajimoto et 
al. [30] recently demonstrated that continuous activation 
of the S1P1 receptor and subsequent G protein signaling 
by Gβγ subunits/Rho family GTPases regulates F-actin 
formation on multi-vesicular bodies required for cargo 
sorting into exosomal intralumenal vesicles. Continuous 
G protein signaling on endosomes has been demonstrated 
by certain so-called class B GPCRs that contain serine/
threonine clusters (phosphorylation acceptor sites) in the 
C-terminal tail [31] that is required for stable β-arrestin 
binding. Thus, angiotensin II type 1 receptor (AT1R) 
internalization to endosomes and packaging into exosomes 
has been shown to be impaired by silencing β-arrestin1 
and β-arrestin2 [32]. Therefore, exosomal processing of 
S1P2 via endosome trafficking/MVB formation might 
be defined by the presence of serine/threonine clusters 
in the C-terminal tail of S1P2 and therefore its ability to 
form stable complexes with β-arrestin. Indeed, S1P1, S1P2 
and S1P4 contain such serine/threonine clusters in their 
C-terminal tails.
The S1P2 antagonist, JTE-013 failed to block the 
CM-stimulated activation of ERK-1/2, suggesting that 
the S1P2 that is taken up and processed by fibroblasts 
becomes constitutively active. Therefore, the response is 
not blocked by JTE-013, which functions as a competitive 
antagonist with S1P for S1P2. We have also demonstrated 
here that a truncated form of S1P2 lacking the N-terminal 
sequence region that contributes to the ligand binding 
site led to the constitutive activation of ERK-1/2 when 
expressed in HEK293 cells. Constitutive activation 
of S1P2 might therefore occur as a consequence of 
proteolysis at the N-terminus, which may normally serve 
to tension TM1 and (in the absence of bound agonist) 
stabilise an inactive basal-state conformation to constrain 
S1P2 signaling. Removal of the N-terminal sequence 
would relieve this inhibitory constraint. The ability of the 
short constitutively active form of S1P2 to stimulate the 
ERK-1/2 pathway occurs presumably because the receptor 
adopts a specific conformation that is generated after 
removal of the N-terminus and that enables formation of 
active signaling complexes that are competent to regulate 
the ERK-1/2 pathway.
There are other examples where N-terminal 
proteolysis of GPCRs can modulate signaling. First, 
protease activated receptors (PARs) contain their 
own ligand within their N-terminal regions [33]. This 
‘tethered ligand’ becomes accessible and able to activate 
the receptor when the N-terminus is proteolysed by, 
for instance, thrombin or trypsin. In addition, the 
thyroid-stimulating hormone (TSH) receptor is subject 
to a metalloprotease-mediated cleavage between the 
membrane-spanning domain and the large N-terminal 
extracellular domain of the receptor and this leads to 
activation of the receptor by removal of an inhibitory 
N-terminal domain, without requirement for a tethered 
ligand. The extracellular domain suppresses constitutive 
activity of the transmembrane domain of the human TSH 
receptor [34, 35]. GPCRs can also be inactivated by 
N-terminal proteolysis e.g. GPR37L1 (an orphan GPCR) 
[36] and the endothelin ETB receptor [37].
Our findings point to a novel functional signaling 
role for the processed short form of S1P2 that is released 
from breast cancer cells in its native form in exosomes. 
The question remains as to whether this short form 
of the receptor has a role in regulating inter-cellular 
communication between cancer cells and fibroblasts and 
whether it can enhance metastatic spread. It is tempting 
to speculate that the exosomal release of S1P2 and its 
subsequent processing may have a role because exosomal 
cargoes do play a role in tumour dissemination by 
influencing and modulating the tumour microenvironment, 
enabling stromal cells to receive oncogenic and pro-
angiogenic signals [38–41]. There are numerous examples 
of communication between cancer cells and recipient cells 
involving exosomes in cancer. For instance, exosomes 
derived from nasopharyngeal carcinoma contain latent 
membrane protein 1 (LMP1) and are able to induce ERK 
and AKT activation in the recipient cells, such as epithelial 
cells, endothelial cells and fibroblasts [42]. In addition, 
mesenchymal stem cell-derived exosomes regulate MCF-7 
breast cancer cell migration involving Wnt signaling [43]. 
We have shown that the short form of S1P2 can promote 
fibroblast proliferation, although it will be important to 
establish whether a similar mechanism operates in tumour-
associated fibroblasts. The processed short S1P2 receptor 
might function to increase proliferation and therefore the 
number of fibroblasts that can then be programmed by 
other factors to undergo transformation to myofibroblasts 
capable of communicating with cancer cells to promote 
their dissemination.
Future studies will require characterisation of the 
signaling properties of the short S1P2 receptor and its role 
in metastatic spread, particularly with regard to tumour-
associated fibroblasts. This can be explored by over-
expression of the short S1P2 form in tumour-associated 
fibroblasts in vivo in order to establish the effect on 
metastatic spread in breast cancer orthotopic mouse 
models. In conclusion, our current findings establish a 
novel role of S1P2 in the cancer cell-fibroblast interaction.
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MATERIALS AND METHODS
Materials
All biochemicals were from Sigma-Aldrich (Poole, 
UK) unless indicated otherwise. Cell culture media and 
antibiotics were from Gibco (Paisley, UK) and foetal calf 
serum from Sera Laboratories International (Haywards 
Heath, UK). Plasmid constructs for pEGFP hsp70 (# 
15215) and pEF6. mCherry-tsg101 (# 38318) were from 
Addgene (Cambridge, MA, USA) and for HA-tagged 
S1P2 (EDG050TN000) from UMR cDNA Resource 
Center (Bloomsberg, USA). Lipofectamine 2000™ was 
from Invitrogen (Leicester, UK), ON-TARGETplus 
SMARTpool® S1P2 siRNA and DharmaFECT 4 from 
Dharmacon (Cromlington, UK), scrambled siRNA 
(ALLSTARS Negative control) and endotoxin-free 
plasmid preparation kits from Qiagen (Manchester, UK). 
Antibodies employed detected S1P2 (PA5-23208) and 
CD63 (10628D) (ThermoFisher Scientific, UK), S1P4 
(CAY13489, Cambridge Bioscience Ltd, Cambridge, 
UK), ERK-2 (610104, BD Biosciences, UK), actin 
(A2066, Sigma-Aldrich, UK), mCherry (TA150125, 
OriGene EU, Herford, Germany) and, from Insight 
Biotechnology Ltd (Wembley, UK), GFP (sc-9996), 
HA-tag (sc-7392) and phospho-ERK-1/2 (sc-7383). 
Methyl-[3H] thymidine (NET027L) was purchased from 
Perkin Elmer (Buckinghamshire, UK). CYM5520 and 
JTE-013 were purchased from Cambridge Biosciences 
(Cambridge, UK). VECTASHIELD® Hard Set™ 
Mounting Medium with DAPI was purchased from 
Vector Laboratories Ltd (Peterborough, UK).
Cell culture
MDA-MB-231 and MDA-MB-453 breast cancer 
cells, mouse embryonic fibroblasts (MEFs) and HEK293 
cells were maintained in Dulbecco’s modified Eagle’s 
media (DMEM) with Glutamax containing 10% (v/v) 
European foetal calf serum (EFCS) and 1% (v/v), 
penicillin and streptomycin (Pen-Strep) in humidified 
conditions at 37 °C in 95% air/5% CO2.
S1P2 cloning
N-Terminal 3x HA-tagged full-length human S1P2 
in pcDNA3.1(+) was used to create N-terminal 1x and 
2x HA-tagged truncated versions of human S1P2 lacking 
the first 37 amino acids from the predicted amino acid 
sequence of S1P2 via sub-cloning. All of the plasmid 
DNA used in this study was purified using endotoxin-
free plasmid preparation kits and their sequences 
validated by Sanger sequencing (GATC, Cologne, 
Germany).
Transfection with DNA
MDA-MB-231 breast cancer cells were seeded in 
75 cm2 flasks at 3 x 106 cells/ml complete medium. At 
approximately 75% confluence, the medium was replaced 
with Opti-MEM (10 ml) and the cells transfected with 10 
μg of DNA plasmid, using Lipofectamine ™ 2000 and 
incubated for 24 hours. Plasmid constructs encoded either 
pEGFP hsp70, pEF6. mCherry-tsg101 or N-terminal 3x 
HA-tagged S1P2. HEK293 cells, grown in 12 well plates, 
were transfected with 1 μg DNA per well using plasmid 
encoding N-terminal 3x HA-tagged S1P2 or N-terminal 
1x or 2x HA-tagged truncated S1P2 and Lipofectamine 
™ 2000 for 24 hours, according to the manufacturer’s 
instructions.
Transfection with siRNA
MDA-MB-231 cells at approximately 60% 
confluence were treated with scrambled siRNA or S1P2 
siRNA oligonucleotide at a final concentration of 100-200 
nM in antibiotic-free DMEM and 10% (v/v) EFCS using 
DharmaFECT 4 and incubated for 24 hours.
Cell lysate preparation
Cells were lysed in SDS-PAGE sample buffer 
containing SDS, 0.5% (w/v), Tris, 62.5 mM, pH 6.7, 
EDTA, 1.25 mM, sodium pyrophosphate, 0.5 mM, DTT, 
50 mM, bromophenol blue, 0.06% (w/v) and glycerol, 
12.5% (v/v).
Western blotting
Western blot analysis was performed as described 
in [44].
[3H] thymidine incorporation and P-ERK-1/2 
assay
MEFs were grown to approximately 75-80% 
confluency on 24 wells plates before quiescing in DMEM 
for 24 hours. MEFs were then treated with NCM or CM 
for 10 min and samples taken for western blot analysis 
with anti-phospho ERK-1/2 antibody. MEFs were also 
treated with CM for 24 hours and [3H] thymidine (9.25 
kBq/ml) was added to each well for the final 5 hours. 
Incubations were terminated by replacing the medium 
with a brief wash of 1 ml ice cold PBS, followed by the 
addition of 1 ml ice cold 10% (w/v) TCA for 10 minutes. 
After 3 x 10 minute washes with TCA (10% w/v), 0.25 ml 
of 0.1% (w/v) SDS with 0.3 M NaOH was added to each 
well, the samples transferred to scintillation fluid and the 
radioactivity incorporated into newly synthesised DNA 
quantified by scintillation counting.
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Conditioned medium
MDA-MB-231 or MDA-MB-453 breast cancer cells 
were seeded in 75cm2 flask at 3 x 106 cells/ml complete 
medium and grown to approximately 75% confluence. 
The adhered cells were gently washed twice with 10 ml of 
Opti-MEM and then incubated with 10 ml/flask of fresh 
Opti-MEM for 48 hours before collection of the medium. 
Cell debris was removed by centrifugation (180g, 5 
minutes). The resulting supernatant was filtered (0.22 μm, 
Merck Millipore) to produce conditioned medium (CM). 
Where indicated, MDA-MB-231 cells were transiently 
transfected with GFP-hsp70 or mCherry tsg101 or HA-
S1P2 plasmid construct.
Protein precipitation
CM was mixed with 125 μl of 6 M TCA per 1 ml 
of CM and the mixture was shaken well and incubated on 
ice for a minimum of 2 hours. Following incubation the 
mixture was transferred into centrifuge tubes (Beckman, 
Z50901SCA) and centrifuged at 16,125 g at 4 °C for 
10 minutes using SW40Ti rotor in Beckman-Coulter 
ultracentrifuge XL-100K. The supernatant was discarded 
and pellets (PPT) re-suspended in 40 μl of 9 M urea in 50 
mM Tris (pH 7.5). SDS-PAGE sample buffer was added 
and 2M Tris to neutralise. Samples were stored at -20 °C 
for future western blot analysis.
Isolation of exosomes
Conditioned media from a minimum of three 75cm2 
flasks of MDA-MB-231 cells was centrifuged at 20,000 
g (4°C, 30 minutes) and the resulting supernatant ultra-
centrifuged at 100,000 g at 4 °C for 75 minutes. The 
exosome pellet was re-suspended in 1 ml of sterile filtered 
phosphate buffered saline (PBS) pH 7.4 at 4 °C and the 
ultra-centrifugation step repeated to further purify the 
exosomes. The final exosome pellet was re-suspended in 
250μl sterile filtered PBS, pH 7.4 and stored at -80°C.
Immunofluorescence microscopy
MEFs or MDA-MB-231 cells were seeded at 
density of 50 x 104 cells/ml complete medium on 13 mm 
cover slips in a 12 well plate. MEFs were quiesced for 24 
hr before treatment with either non-conditioned medium 
(NCM + Opti-MEM) or CM or CYM5520. Cells on 
coverslips were washed with cold PBS pH 7.4, fixed with 
3.7% (v/v) formaldehyde in PBS pH 7.4 at 4 °C for 10 
minutes and permeabilized with 0.1% (v/v) Triton X-100 
in PBS pH 7.4 (1ml/well) for 2 minutes. After two washes 
with cold PBS pH 7.4, non-specific binding of antibodies 
was blocked using blocking solution containing 5% (v/v) 
EFCS, 10 mg/ml BSA in PBS pH 7.4 for 30 minutes. 
Proteins of interest were detected using specific antibodies 
(diluted 1:100 with blocking solution), incubated for 1 
hour at room temperature. After washing three times with 
ice cold PBS pH 7.4, secondary antibodies conjugated to 
either TRITC or FITC or Texas Red (diluted 1:100 with 
blocking solution) were used to detect proteins of interest. 
Coverslips were mounted using VECTASHIELD® Hard 
Set™ Mounting Medium with DAPI. Samples were stored 
at 4 °C or directly examined for immunofluorescence by 
confocal microscopy (Leica TCS SP5).
Electron microscopy detection of exosome 
proteins using immuno-gold labelling
Exosomes were re-suspended in an equal volume 
of 4% paraformaldehyde/PBS and 5 μl droplets of 
placed onto poly-L-lysine/carbon coated nickel grids. 
Grids were washed (6 x 1 minute) with PBS to remove 
paraformaldehyde followed by 0.05 M Glycine/PBS (3 
x 5 minutes) before blocking with 3% BSA/PBS (3 x 5 
minutes) and then adding anti-CD63 antibody (1:100), 
anti-S1P2 antibody (1:100) or no antibody (blocking 
solution only). After 1 hour, the grids were washed with 
3% BSA/PBS (6 x 5 minutes) before incubation (1 hour) 
with gold-labelled secondary antibodies. Gold (15 nm)-
labelled goat anti-mouse IgG (1:20) was used to detect 
CD63; gold (10 nm)-labelled anti-rabbit IgG (1:20) to 
detect S1P2. No antibody controls were processed with 
both gold-labelled secondary antibodies. After further 
washes with blocking buffer (6 x 5 minutes) and PBS (6 
x 5 minutes), grids were prepared for visualisation and 
imaged using a Gatan Multiscan 794 camera and a 200 kV 
FEG high resolution FEI Tecnai T20 transmission electron 
microscope
Densitometirc and statistical analysis
Densitometric values quantified using ImageJ 
were expressed as the ratio of P-ERK/actin (represented 
as mean +/− SEM for fold changes, n=3 experiments). 
Statistical analysis was undertaken using one way ANOVA 
or t-test and considered significant when *p < 0.05.
Abbreviations
CM: conditioned medium; CYM5520: 
1-[2-[2,5-dimethyl-1-(phenylmethyl)-1H-pyrrol-3-yl]-
2-oxoethyl]-1,6-dihydro-6-oxo-3-pyridinecarbonitrile; 
EMT: epithelial-mesenchymal transition; ERK-1/2: 
extracellular signal regulated kinase 1/2; EV: extracellular 
vesicles; GPCR: G protein-coupled receptor; hsp70: 
heat shock protein 70; JTE-013: 1-[1,3-dimethyl-4- 
(2-methylethyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-4-(3,5- 
dichloro-4-pyridinyl)-semicarbazide; MEF: mouse 
embryonic fibroblasts; MVB: multi-vesicular bodies; 
NCM: non-conditioned medium; S1P2: sphingosine 
1-phosphate receptor 2; S1P: sphingosine 1-phosphate; 
SK1: sphingosine kinase 1; SK2: sphingosine kinase 2; 
TM: transmembrane domain; tsg101: tumor susceptibility 
gene 101.
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